Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
The antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) is a promising treatment for EGFR inhibitor-resistant ...
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
and Daiichi Sankyo is attempting to gain approval for its ADC patritumab deruxtecan. AstraZeneca, which also has a cancer drug partnership with Daiichi, markets Imfinzi and Tagrisso for several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback